https://www.selleckchem.com/pr....oducts/usp25-28-inhi
rpretation are recommended. Copyright © 2019 Ochodo EA et al.Background Protozoan Leishmania parasites are responsible for a range of clinical infections that represent a substantial challenge for global health. Amphotericin B (Am is increasingly used to treat Leishmania infection, so understanding the potential for resistance to this drug is an important priority. Previously we described four independently-derived AmB-resistant L. mexicana lines that exhibited resistance-associated genetic lesions resulting in altered
Like
Comment
Share
